VIVUS Inc. and its subsidiaries voluntarily filed a prepackaged Chapter 11 reorganization plan in Delaware bankruptcy court Tuesday under which the California-based biopharmaceutical company would become a wholly owned subsidiary of Carl Icahn's investment firm Icahn Enterprise Holdings LP.